Introduction to STOML3, A Potential Drug Target (G161003)

Target Name: STOML3

NCBI ID: G161003

STOML3

Introduction to STOML3, A Potential Drug Target

STOML3 (Stomatin-like protein 3), also known as SLP-3, is a protein that has gained increasing attention as a potential drug target and biomarker in various diseases. This article will provide an in-depth review of STOML3, highlighting its structure, functions, potential roles in diseases, and its therapeutic implications.

Structure and Functions of STOML3

STOML3 is a member of the stomatin protein family, which plays important roles in membrane processes, including ion transport, mechanosensation, and lipid organization. It is a small protein of approximately 33 kDa, consisting of 287 amino acids. Structurally, STOML3 contains a conserved stomatin domain (amino acids 22-244), which is crucial for its dimerization and membrane association.

Functionally, STOML3 has been implicated in a wide range of cellular processes. It is primarily found in the plasma membrane, where it interacts with various ion channels and transporters, influencing their activity and localization. STOML3 has been shown to regulate the activity of several important ion channels, including the sodium/proton exchangers, NHE1 and NHE3, as well as the inwardly rectifying potassium channel, Kir6.2. Additionally, STOML3 has been suggested to play a role in cellular responses to mechanical stimuli, such as cell volume regulation and mechanosensitive ion channels.

STOML3 as a Biomarker

The dysregulation of STOML3 expression has been observed in various diseases, suggesting its potential as a valuable biomarker. For instance, in cancers, altered STOML3 expression has been reported in breast, ovarian, and lung cancers. In breast cancer, increased STOML3 expression has been associated with poor prognosis and aggressive tumor characteristics. Similarly, decreased expression of STOML3 has been correlated with advanced stages of ovarian cancer. These findings open up the possibility of using STOML3 expression levels as diagnostic or prognostic markers in these malignancies.

Furthermore, STOML3 has also been implicated in neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. Studies have shown that STOML3 interacts with certain proteins involved in the pathogenesis of these diseases, including amyloid-beta precursor protein (APP) and alpha-synuclein. The dysregulation of STOML3 may affect the processing and aggregation of these proteins, contributing to neurodegeneration. Therefore, measuring STOML3 levels in cerebrospinal fluid or brain tissues could provide insight into the progression of these diseases and aid in diagnosis and prognosis.

Therapeutic Implications

Given the diverse functions of STOML3 and its association with various diseases, targeting this protein holds significant therapeutic potential. For instance, in cancers where STOML3 is overexpressed, developing strategies to inhibit its activity or disrupt its interactions with relevant ion channels and transporters could serve as a promising therapeutic approach. This could potentially modulate cellular processes influenced by STOML3 and halt tumor progression.

In neurodegenerative diseases, therapeutically targeting STOML3 may offer new avenues for intervention. By manipulating STOML3-mediated protein interactions or modulating its expression, it may be possible to affect the aggregation of disease-associated proteins, ultimately slowing down or preventing neurodegeneration. However, further preclinical and clinical studies are needed to validate the efficacy and safety of targeting STOML3 in these diseases.

Conclusion

STOML3 is an intriguing protein that has emerged as a drug target and biomarker in various diseases. Its structural and functional characteristics highlight its importance in membrane processes and ion channel regulation. The dysregulation of STOML3 expression in cancers and neurodegenerative diseases suggests its potential as a biomarker for diagnosis, prognosis, and disease progression monitoring. Moreover, therapeutic interventions targeting STOML3 may represent promising strategies for future drug development. Continued research on STOML3 will undoubtedly provide further insights into its roles and therapeutic implications, paving the way for novel treatments against diseases where STOML3 is involved.

Protein Name: Stomatin Like 3

Functions: Required for the function of many mechanoreceptors. Modulate mechanotransduction channels and acid-sensing ion channels (ASIC) proteins. Potentiates PIEZO1 and PIEZO2 function by increasing their sensitivity to mechanical stimulations

The "STOML3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STOML3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets